How has Siegfried expanded capabilities through M&A?

We acquired two Novartis manufacturing sites in Spain, enhancing our drug product footprint with innovative oral, inhalative and sterile forms. In 2023, we acquired DINAMIQS, entering preclinical activities in biological active ingredient production. In November 2024, we opened a 4,500 m² R&D center in Evionnaz, Switzerland, strengthening our development capabilities. Two years prior, we launched a drug product development center at our Barberà del Vallès site in Barcelona.

In June 2024 we acquired Curia Global’s site in Grafton, Wisconsin. It is specialized in early-phase development and manufacturing services. The facility further reinforces our early development entry point and speed to clinical capabilities, which is why we call it the Siegfried Acceleration Hub. How will Siegfried meet the growing demand for evolving therapeutic needs?

Biological drugs represent the future, but chemical drugs still play a vital role — and Siegfried offers both. We have a strong footprint in biologics, including vector technologies and fill-finish capabilities for large biological drugs. We proved our agility by rapidly scaling up vaccine production during the pandemic. Our broad platform portfolio serves customers with vials, prefilled syringes, cartridges, and ampoules. At the early stage, if a customer’s needs evolve, they can easily switch between these formats. We support them from phase 1 to commercial, providing speed to market without the need to change CDMOs.

As molecules become more potent and complex, our capabilities in both small- and large-scale high-potent manufacturing stand out. Our Drug Substances and Drug Products clusters offer the full spectrum of technologies. With a global footprint across the US, Europe, and China, we are well-positioned to serve key markets. Our size and infrastructure enable us to meet stringent regulatory demands — like the latest Annex 1 requirements for sterile processes. How does Siegfried advance cell and gene therapies (CGT)?

CGT are a young modality with great momentum. More products are reaching commercial stage. Biotech and pharma companies face significant safety and CMC challenges during clinical trials. Siegfried, bolstered by our DINAMIQS division, plays a crucial role in overcoming these challenges, especially in early clinical phases. For example, Siegfried DINAMIQS experts optimized viral vector cassettes to enhance gene expression in the body and developed processes for novel capsids to improve targeted tissue delivery. We also develop comprehensive analytical strategies and provide in-house analytical services, ensuring that insights gained inform subsequent steps towards GMP. This approach helps improve GMP batch success rates and yields, keeping manufacturing costs competitive. Siegfried DINAMIQS bridges drug design and process development in the CGT space. In CGT, we are truly a CRDMO (Contract Research, Development, and Manufacturing Organization), standing at the forefront of science, technology, and state-of-the-art GMP practices. How does Siegfried’s inclusion in the Dow Jones Sustainability Index exemplify the firm’s approach to sustainability?

Siegfried has been included in the Dow Jones Best-In-Class Europe Index (formerly Dow Jones Sustainability Index Europe) for four consecutive years, making it the only CDMO to be represented. We address critical issues such as resource depletion, waste generation, greenhouse gas emissions, water and soil pollution, and energy reduction. Our corporate governance, overseen by our Board of Directors, ensures global implementation of sustainability practices.

Siegfried’s sustainability efforts are measured through several key initiatives. Notable achievements include a 46% reduction in carbon emissions, a 34% reduction in waste, and a 32% reduction in water consumption (all normalized to sales and a 2020 baseline). We are committed to developing more sustainable products by assessing the environmental footprint of our customers’ products and identifying opportunities for improvement using green chemistry principles. By integrating sustainability into our business operations, we not only reduce our environmental footprint but also achieve cost savings and position ourselves as a CDMO sustainability leader. What are Siegfried's growth plans and general objectives in 2025?

Siegfried's objective is to follow through on our EVOLVE+ strategy and to grow our business both organically and through value accretive acquisitions. In 2025, we will continue to broaden our technology offerings, such as in spray drying and pre-filled syringes, and will focus on further strengthening our development, commercial, and operational excellence. Our strategy EVOLVE+ is geared towards the long-term trends in our industry and we expect to continue to grow profitably year after year.